SCHEMBL4095748

SCHEMBL4095748

CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(OCCN3CCOCC3)c(OC)cc2OC)ncc1Br

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ULK1 O75385 3/20 0.70
ZAP70 P43403 10/20 0.61
ALK Q9UM73 3/20 0.58
FGFR3 P22607 2/20 0.58
KDR P35968 2/20 0.58
EGFR P00533 2/20 0.58
JAK2 O60674 2/20 0.58
CDC7 O00311 1/20 0.58
PLK4 O00444 1/20 0.58
CHEK1 O14757 1/20 0.58
AURKA O14965 1/20 0.58
DCLK1 O15075 1/20 0.58
PDPK1 O15530 1/20 0.58
DAPK3 O43293 1/20 0.58
ROCK2 O75116 1/20 0.58
PRKD3 O94806 1/20 0.58
MAP4K4 O95819 1/20 0.58
PAK4 O96013 1/20 0.58
CHEK2 O96017 1/20 0.58
ERBB2 P04626 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12729507 0.91 ULK1 (0.67) ULK1ZAP70ALKFGFR3KDR
SCHEMBL4096263 0.86 ULK1 (0.80) ULK1ZAP70ALKFGFR3KDR
SCHEMBL4102950 0.86 ULK1 (0.80) ULK1ZAP70ALKFGFR3KDR
SCHEMBL1912110 0.84 ZAP70 (0.69) ULK1ZAP70ALKFGFR3KDR
SCHEMBL4089495 0.83 ZAP70 (0.68) ULK1ZAP70ALKFGFR3KDR
SCHEMBL12729336 0.83 ZAP70 (0.68) ULK1ZAP70ALKFGFR3KDR
SCHEMBL4099214 0.83 ULK1 (0.57) ULK1ZAP70ALKFGFR3KDR
SCHEMBL29900883 0.82 ULK1 (1.00) ULK1ZAP70ALKFGFR3KDR
SCHEMBL375608 0.82 ULK1 (1.00) ULK1ZAP70ALKFGFR3KDR
SCHEMBL380944 0.82 ULK1 (0.88) ULK1ZAP70ALKFGFR3KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090131436-A1 Pyrimidine Derivatives NOVARTIS AG (CH) 2009-05-21 US claimed
EP-1784392-A2 PYRIMIDINE DERIVATIVES Novartis AG (CH) 2007-05-16 EP claimed
WO-2006021454-A2 PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2006-03-02 WO claimed
US-20090131436-A1 Pyrimidine Derivatives NOVARTIS AG (CH) 2009-05-21 US disclosed
EP-1784392-A2 PYRIMIDINE DERIVATIVES Novartis AG (CH) 2007-05-16 EP disclosed
WO-2006021454-A2 PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2006-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131436-A1 Pyrimidine Derivatives DPYD, TYMP, TYMS ULK1 1714/4885ZAP70 1678/4885ALK 2060/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.